ArticleNature communications2025
In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives.Cancer biology & medicine · 2026Review
- Spatiotemporally Controlled Bioorthogonal Prodrug Activation for Precise Chemotherapy.Small science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Targeted protein degradation has emerged as a promising anticancer strategy. Bringing disease-related proteins into proximity with the degradation system is crucial but often hindered by the availability of suitable ligands for proteins of interest (POIs). In this study, we utilize the interactions between intracellular supramolecular nanofibers and certain guest proteins to establish a ligand-free strategy for protein degradation. As the enterokinase (ENTK)-instructed supramolecular assemblies interact with the histone protein H2B for its translocation, the tetrazine-bearing supramolecular nanofibers conjugate with a cereblon E3 ligase ligand to recruit CRBN and directly degrade wild-type H2B. Using the same bioorthogonal ligation, another reactive oxygen species (ROS)-induced supramolecular assemblies localize to mitochondria and efficiently degrade Cofilin-2. Both in situ formed intracellular supramolecular assemblies are dependent on cancer-related conditions (either overexpressed enzymes or overproduced ROS), owning the merit of cell selectivity. These assemblies synergize with bioorthogonal ligation to exhibit significant biological activities, including chemotherapeutic sensitization and induced apoptosis, thereby inhibiting cancer cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.